Sophia Sanjay

Sophia Sanjay

@aidigihealth

3 Beiträge

0 Fotos

0 Videos

Lebt in Springfield

Von Mumbai City

Male

Veranstaltungen

Web Marketing Executive als WiseGuy Reports

Von 2005-2006 WEB MARKETING als Harvard University

Klasse von MBA in Healthcare

Neueste Updates

Sophia Sanjay @aidigihealth hat ein neuen Blog hinzugefügt in Health
2025-11-06 10:08:05 ·

Regulatory Bodies Navigate Complexity to Accelerate Personalized Medicine Approvals; Balancing Innovation with Safety in a Dynamic Market

Regulatory approval processes are critical to the personalized medicine market’s growth, yet they face unique challenges. Unlike traditional drugs, personalized therapies often target rare genetic subtypes, have smaller patient cohorts, and rely on novel biomarkers—factors that complicate traditional efficacy and safety assessments. Agencies like the FDA, EMA, and China’s NMPA...

0 Kommentare ·0 Geteilt ·16 Ansichten ·0 Bewertungen

Bitte loggen Sie sich ein, um liken, teilen und zu kommentieren!
Sophia Sanjay @aidigihealth hat ein neuen Blog hinzugefügt in Health
2025-11-06 09:49:10 ·

Tech-Driven Evolution: AI and Digital Tools Reshape India’s CRO Sector for Faster Drug Development

India’s contract research organizations (CROs) are undergoing a technological revolution, with artificial intelligence (AI), machine learning (ML), and advanced analytics driving efficiency and innovation across drug development workflows. From preclinical data analysis to post-trial reporting, CROs are leveraging digital tools to reduce timelines, minimize errors, and lower costs,...

0 Kommentare ·0 Geteilt ·17 Ansichten ·0 Bewertungen

Bitte loggen Sie sich ein, um liken, teilen und zu kommentieren!
Sophia Sanjay @aidigihealth hat ein neuen Blog hinzugefügt in Health
2025-11-06 09:33:13 ·

Patent Expirations Ignite Generic Injectables Market Expansion: Key Drugs and Industry Responses

A wave of patent expirations for high-revenue branded injectables is propelling the generic injectables market into uncharted territory. Over the next five years, patents for drugs like adalimumab (Humira, though biosimilar), pantoprazole, and cisplatin are set to expire, opening multi-billion-dollar opportunities for generic manufacturers. This trend not only lowers patient costs but also...

0 Kommentare ·0 Geteilt ·15 Ansichten ·0 Bewertungen

Bitte loggen Sie sich ein, um liken, teilen und zu kommentieren!

Mehr Storys